These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 35766022)

  • 1. Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).
    Schulze PC; Bogoviku J; Westphal J; Aftanski P; Haertel F; Grund S; von Haehling S; Schumacher U; Möbius-Winkler S; Busch M
    Circulation; 2022 Jul; 146(4):289-298. PubMed ID: 35766022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
    Tamaki S; Yamada T; Watanabe T; Morita T; Furukawa Y; Kawasaki M; Kikuchi A; Kawai T; Seo M; Abe M; Nakamura J; Yamamoto K; Kayama K; Kawahira M; Tanabe K; Fujikawa K; Hata M; Fujita Y; Umayahara Y; Taniuchi S; Sanada S; Shintani A; Fukunami M
    Circ Heart Fail; 2021 Mar; 14(3):e007048. PubMed ID: 33663235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
    Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF).
    Damman K; Beusekamp JC; Boorsma EM; Swart HP; Smilde TDJ; Elvan A; van Eck JWM; Heerspink HJL; Voors AA
    Eur J Heart Fail; 2020 Apr; 22(4):713-722. PubMed ID: 31912605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal and Cardiovascular Effects of sodium-glucose cotransporter 2 (SGLT2) inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure (RECEDE-CHF): protocol for a randomised controlled double-blind cross-over trial.
    Mordi NA; Mordi IR; Singh JS; Baig F; Choy AM; McCrimmon RJ; Struthers AD; Lang CC
    BMJ Open; 2017 Oct; 7(10):e018097. PubMed ID: 29042392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin Effects on Pulmonary Artery Pressure in Patients With Heart Failure: Results From the EMBRACE-HF Trial.
    Nassif ME; Qintar M; Windsor SL; Jermyn R; Shavelle DM; Tang F; Lamba S; Bhatt K; Brush J; Civitello A; Gordon R; Jonsson O; Lampert B; Pelzel J; Kosiborod MN
    Circulation; 2021 Apr; 143(17):1673-1686. PubMed ID: 33550815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial.
    Martens P; Dauw J; Verbrugge FH; Nijst P; Meekers E; Augusto SN; Ter Maaten JM; Damman K; Mebazaa A; Filippatos G; Ruschitzka F; Tang WHW; Dupont M; Mullens W
    Circulation; 2023 Jan; 147(3):201-211. PubMed ID: 36335479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload.
    Mullens W; Dauw J; Martens P; Verbrugge FH; Nijst P; Meekers E; Tartaglia K; Chenot F; Moubayed S; Dierckx R; Blouard P; Troisfontaines P; Derthoo D; Smolders W; Bruckers L; Droogne W; Ter Maaten JM; Damman K; Lassus J; Mebazaa A; Filippatos G; Ruschitzka F; Dupont M;
    N Engl J Med; 2022 Sep; 387(13):1185-1195. PubMed ID: 36027559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
    Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
    Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects.
    Griffin M; Rao VS; Ivey-Miranda J; Fleming J; Mahoney D; Maulion C; Suda N; Siwakoti K; Ahmad T; Jacoby D; Riello R; Bellumkonda L; Cox Z; Collins S; Jeon S; Turner JM; Wilson FP; Butler J; Inzucchi SE; Testani JM
    Circulation; 2020 Sep; 142(11):1028-1039. PubMed ID: 32410463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure.
    Pérez-Belmonte LM; Sanz-Cánovas J; Millán-Gómez M; Osuna-Sánchez J; López-Sampalo A; Ricci M; Jiménez-Navarro M; López-Carmona MD; Bernal-López MR; Barbancho MA; Lara JP; Gómez-Huelgas R
    J Am Geriatr Soc; 2022 Mar; 70(3):862-871. PubMed ID: 34843628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure.
    Boorsma EM; Beusekamp JC; Ter Maaten JM; Figarska SM; Danser AHJ; van Veldhuisen DJ; van der Meer P; Heerspink HJL; Damman K; Voors AA
    Eur J Heart Fail; 2021 Jan; 23(1):68-78. PubMed ID: 33251643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diuretic strategies in patients with acute decompensated heart failure.
    Felker GM; Lee KL; Bull DA; Redfield MM; Stevenson LW; Goldsmith SR; LeWinter MM; Deswal A; Rouleau JL; Ofili EO; Anstrom KJ; Hernandez AF; McNulty SE; Velazquez EJ; Kfoury AG; Chen HH; Givertz MM; Semigran MJ; Bart BA; Mascette AM; Braunwald E; O'Connor CM;
    N Engl J Med; 2011 Mar; 364(9):797-805. PubMed ID: 21366472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial.
    Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Carson P; Anand I; Doehner W; Haass M; Komajda M; Miller A; Pehrson S; Teerlink JR; Brueckmann M; Jamal W; Zeller C; Schnaidt S; Zannad F
    Circulation; 2021 Jan; 143(4):326-336. PubMed ID: 33081531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.
    Packer M; Butler J; Zeller C; Pocock SJ; Brueckmann M; Ferreira JP; Filippatos G; Usman MS; Zannad F; Anker SD
    Circulation; 2023 Sep; 148(13):1011-1022. PubMed ID: 37621153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
    Connelly KA; Mazer CD; Puar P; Teoh H; Wang CH; Mason T; Akhavein F; Chang CW; Liu MH; Yang NI; Chen WS; Juan YH; Opingari E; Salyani Y; Barbour W; Pasricha A; Ahmed S; Kosmopoulos A; Verma R; Moroney M; Bakbak E; Krishnaraj A; Bhatt DL; Butler J; Kosiborod MN; Lam CSP; Hess DA; Rizzi Coelho-Filho O; Lafreniere-Roula M; Thorpe KE; Quan A; Leiter LA; Yan AT; Verma S
    Circulation; 2023 Jan; 147(4):284-295. PubMed ID: 36335517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure.
    Thiele K; Rau M; Hartmann NK; Möller M; Möllmann J; Jankowski J; Keszei AP; Böhm M; Floege J; Marx N; Lehrke M
    ESC Heart Fail; 2022 Aug; 9(4):2233-2238. PubMed ID: 35611683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study.
    Charaya K; Shchekochikhin D; Andreev D; Dyachuk I; Tarasenko S; Poltavskaya M; Mesitskaya D; Bogdanova A; Ananicheva N; Kuzub A
    Open Heart; 2022 May; 9(1):. PubMed ID: 35609943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.